Platelet Lysate Nebulization Protocol for the Treatment of COVID-19 and Its Sequels: Proof of Concept and Scientific Rationale

Int J Mol Sci. 2021 Feb 12;22(4):1856. doi: 10.3390/ijms22041856.


One of the most severe effects of coronavirus disease 2019 (COVID-19) is lung disorders such as acute respiratory distress syndrome. In the absence of effective treatments, it is necessary to search for new therapies and therapeutic targets. Platelets play a fundamental role in respiratory disorders resulting from viral infections, being the first line of defense against viruses and essential in maintaining lung function. The direct application of platelet lysate (PL) obtained from the platelet-rich plasma of healthy donors could help in the improvement of the patient due its anti-inflammatory, immunomodulatory, antifibrotic, and repairing effects. This work evaluates PL nebulization by analyzing its levels of growth factors and its biological activity on lung fibroblast cell cultures, besides describing a scientific basis for its use in this kind of pathology. The data of the work suggest that the molecular levels and biological activity of the PL are maintained after nebulization. Airway administration would allow acting directly on the lung tissue modulating inflammation and stimulating reparative processes on key structures such as the alveolocapillary barrier, improving the disease and sequels. The protocol developed in this work is a first step for the study of nebulized PL both in animal experimentation and in clinical trials.

Keywords: COVID-19; growth factors; nebulization; platelet; platelet lysate; platelet-rich plasma.

MeSH terms

  • Adult
  • Animals
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / immunology
  • Anti-Inflammatory Agents / pharmacology*
  • Blood Platelets / immunology
  • COVID-19 / immunology
  • COVID-19 / therapy*
  • Cell Line
  • Female
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / immunology
  • Immunologic Factors / pharmacology*
  • Intercellular Signaling Peptides and Proteins / administration & dosage
  • Intercellular Signaling Peptides and Proteins / immunology
  • Intercellular Signaling Peptides and Proteins / pharmacology*
  • Male
  • Nebulizers and Vaporizers
  • Platelet-Rich Plasma* / immunology
  • SARS-CoV-2 / immunology
  • Treatment Outcome


  • Anti-Inflammatory Agents
  • Immunologic Factors
  • Intercellular Signaling Peptides and Proteins